6185: CanSino Biologics Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

CanSino Biologics Inc.

HKG:6185

SummaryFactSheetFinancial
Price
HK$22.00
Loss Chance
50.9%
3.40JITTA SCORE
657.54%Over Jitta Line
Jitta Ranking
Biotechnology
22 / 61
Health Care
93 / 234
Hong Kong
?
656 / 2,522
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Related
Essex Bio-Technology Limited
HKG:1061
6.96
HK$2.64
63.12%
3SBio
HKG:1530
7.67
HK$16.09
77.20%
Everest Medicines Limited
HKG:1952
4.59
HK$25.50
7.28%
HBM Holdings Limited
HKG:2142
5.46
HK$10.51
10.15%
Mabpharm Private Limited
HKG:2181
n/a
HK$n/a
n/a
Jitta Factors
Growth Opportunity (56)
Recent Business Performance (74)
Financial Strength (48)
Return to Shareholders (8)
Competitive Advantage (43)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
Key Stats
Jitta Score
Jitta Line
3.40
657.54%
3.04
203.42%
3.82
189.55%
Biotechnology
6.96
63.12%
7.67
77.20%
4.59
7.28%
COMPANY DESCRIPTION
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. In addition, it develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. Further, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; and CS-2023 to treat meningitis. The company was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.
cansinotech.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.